Evidence map›Paper›PMID 42240668›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Thyroid dose guidance in elective supraclavicular breast radiotherapy: a national survey of practice patterns in Switzerland.

M S Koch, D R Zwahlen, A Clivio, M Bendahman, D Benzaquen, M Betz, P Canino, D Correia, B De Bari, O Fargier Bochaton and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

M S KochDepartment of Radiation Oncology, Cantonal Hospital Winterthur, 8400, Winterthur, Switzerland.
D R ZwahlenDepartment of Radiation Oncology, Cantonal Hospital Winterthur, 8400, Winterthur, Switzerland.
A ClivioCenter for Radiotherapy Rüti, 8630, Rüti, Switzerland.
M BendahmanDepartment of Radiation Oncology, Hôpital Riviera-Chablais, 1847, Rennaz, Switzerland.
D BenzaquenDepartment of Radiation Oncology, Hôpital de la Tour SA, 1217, Meyrin (Geneva), Switzerland.
M BetzDepartment of Radiation Oncology, Hirslanden Clinique Bois-Cerf, 1006, Lausanne, Switzerland.
P CaninoDepartment of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, 6500, Bellinzona, Switzerland.
D CorreiaDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University Bern, 3010, Bern, Switzerland.
B De BariRadiation Oncology, Réseau Hospitalier Neuchâtelois, 2300, La Chaux-de-Fonds, Switzerland.
O Fargier BochatonSwiss Radiation Oncology Network, Clinique Générale Beaulieu, 1206, Geneva, Switzerland.
T FinazziDepartment of Radiation Oncology, Cantonal Hospital Baden, 5404, Baden, Switzerland.
M GauDepartment of Oncology, Service of Radiation Oncology, Lausanne University Hospital and University of Lausanne, 1005, Lausanne, Switzerland.
G GruberDepartment of Radiation Oncology, Clinic Hirslanden, 8032, Zurich, Switzerland.
R GräterDepartment of Radiation Oncology, Lindenhofgruppe AG, 3012, Bern, Switzerland.
G HenkeDepartment of Radiation Oncology, Cantonal Hospital Münsterlingen, 8596, Münsterlingen, Switzerland.
E HerrmannCenter for Radiation Oncology Biel-Seeland-Berner Jura AG Biel/Bienne, 2503, Biel, Switzerland.
K KhanfirDepartment of Radiation Oncology, Hôpital de Sion CHVR, 1950, Sion, Switzerland.
R KrcekDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, 8091, Zurich, Switzerland.
K LösslDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University Bern, 3010, Bern, Switzerland.
T MaderDepartment of Radiation Oncology, Cantonal Hospital Graubünden Stiftung, 7000, Chur, Switzerland.
O MatzingerSwiss Radiation Oncology Network, Swiss Medical Network, 1272, Genolier, Switzerland.
L NegrettiDepartment of Radiation Oncology, Clinica Luganese SA Sede Moncucco, Gruppo Ospedaliero Moncucco, 6900, Lugano, Switzerland.
C PanjeDepartment of Radiation Oncology, Clinic Hirslanden, 5000, Aarau, Switzerland.
N PéguretDepartment of Radiation Oncology, Hirslanden Clinique des Grangettes SA, 1224, Chêne-Bougeries, Switzerland.
L PlasswilmDepartment of Radiation Oncology, HOCH Health Ostschweiz, Kantonsspital St, Gallen, 9007, St. Gallen, Switzerland.
P TsoutsouDepartment of Radiation Oncology, Geneva University Hospital, 1205, Geneva, Switzerland.
F ZimmermannClinic of Radiotherapy and Radiation Oncology, University Hospital Basel, 4301, Basel, Switzerland.
C OehlerDepartment of Radiation Oncology, Cantonal Hospital Winterthur, 8400, Winterthur, Switzerland. christoph.oehler@ksw.ch.ORCID http://orcid.org/0000-0003-1649-9187

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSupraclavicular fossa (SCF) irradiation is integral to adjuvant radiotherapy (RT) for node-positive breast cancer. Due to anatomical proximity, the thyroid gland is frequently exposed, leading to hypothyroidism in approximately 20-40% of long-term survivors. Despite robust dose-response evidence, thyroid management remains inconsistent and breast cancer-specific dose guidance is lacking. This nationwide survey evaluated current practice patterns regarding thyroid delineation, SCF contouring, and thyroid dose guidance during elective SCF irradiation in Switzerland.

methodsA structured electronic questionnaire was distributed between May and November 2025 to all 30 Swiss radiation oncology centers treating breast cancer. Institutional characteristics, thyroid contouring practices, SCF target delineation, and applied thyroid dose guidance were assessed. Analyses were descriptive only.

resultsThirty-three responses from 25 of 30 centers (83%), including all university hospitals, were analyzed. Modern RT techniques were widely implemented (VMAT 79%, IMRT 15%). Routine thyroid contouring was reported by 91% of respondents, of which 94% used AI-assisted tools. However, only 55% applied explicit thyroid dose guidance. Reported mean thyroid dose (D

conclusionsDespite strong dose-response evidence and widespread availability of advanced RT techniques, thyroid protection during elective SCF irradiation remains inconsistently implemented. These findings reveal a gap between evidence and practice and support the development of harmonized, breast cancer-specific recommendations, including routine thyroid delineation, anatomy-based SCF contouring, and explicit, oncologically safe dose guidance-particularly D

Indexed as

Breast cancerDose constraintsHypothyroidism/etiology (MeSH)Supraclavicular fossa irradiationThyroid gland/radiation effects (MeSH)

Identifiers

PMID42240668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.